SINO BIOPHARM (01177) Surges Over 4% as Subsidiary's HER2 Bispecific ADC Achieves Breakthrough in Breast Cancer Neoadjuvant Therapy

Stock News11-26

SINO BIOPHARM (01177) rose more than 4%, reaching a 2.87% gain at press time to trade at HK$7.16, with a turnover of HK$174 million. The catalyst behind the rally was the online publication of Phase II clinical trial results for TQB2102, a HER2-targeted bispecific antibody-drug conjugate (ADC), in the prestigious Journal of Clinical Oncology (IF 43.4) on November 25. TQB2102, developed by SINO BIOPHARM's subsidiary Chia Tai Tianqing, is an ADC targeting two non-overlapping HER2 epitopes (ECD2 and ECD4). Led by Professor Shao Zhimin's team at Fudan University Shanghai Cancer Center, the study marks the first to demonstrate the efficacy and safety of this dual-epitope HER2 ADC in neoadjuvant breast cancer treatment. A Phase III registration trial is currently underway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment